Inizio strengthens leadership with key hires

Inizio, a commercialisation partner for health and life sciences, has made three senior appointments to drive its next phase of growth.

Colin Stanley has been promoted to chief commercial officer, bringing over 25 years of experience in CRO and commercialisation. 

Remco op den Kelder steps into Colin’s previous role as president of Inizio Advisory, having led Putnam, an Inizio Advisory company, through a period of significant growth.

Meanwhile, Jim Sage joins as president of Inizio Engage, bringing extensive US and international experience from Pfizer, where he played a key role in launching blockbuster brands.

These leadership changes position Inizio to continue innovating and delivering tailored solutions for its biopharma clients worldwide.

Paul Taaffe, chief executive of Inizio, said: “Over the past 12 months, Colin has played a key role in shaping our enterprise commercial model and delivering impact through our connected suite of capabilities. 

“The dramatic success that we saw in pharma clients seeking to connect the expertise across Inizio means we are scaling this model to support our clients at every pivotal milestone from discovery to post-launch.  

 “We are highly fortunate to have Remco and Jim onboard as established leaders in our business.

“Both Remco and Jim’s extensive industry knowledge and expertise will strengthen our reputation for excellence throughout the commercialisation journey, empowering our clients to deliver life-changing therapies to patients.

“I’d like to personally thank Greg for his exceptional service following the 20 years of excellence he has driven for Inizio Engage to make it one of the largest and most integrated global organizations serving the HCP and patient engagement needs of biopharma. 

“Greg is especially qualified to help us focus on some of the most important growth areas for both Inizio and our clients.”

Looking to promote your product/service to SME businesses in your region? Find out how Bdaily can help →